Margaret Anderson COO June 25, 2009 BioEconomy Summit Healthcare Policy Session 2: Affordability and Access Fostering inno...
Components Essential to Successful  Innovation in Disease Research <ul><li>Research roadmaps  </li></ul><ul><li>New techno...
Addressing Challenges  within the Traditional  Research System
Key Issues Affecting Progress <ul><li>Infrastructure </li></ul><ul><li>Institutional stakeholders’  resistance  to changin...
Key Issues Affecting Progress <ul><li>Research Environment </li></ul><ul><li>Highly specialized,  reductionist approach  t...
Valley of Death <ul><li>Basic research is the earliest stage of research, carried out for the advancement of knowledge, wi...
Finding Big Ideas in Small Spaces: New Business Models to  Accelerate Research
Philanthropic Research Funding:  Small in Size, Unique in its Role Foundations and  other private funds ($2.5B) Estimated ...
Finding Big Ideas in Small Spaces The Redstone Acceleration and Innovation Network Passion Capital  De-Risking Investments...
Venture Philanthropies’ Innovative Practices <ul><li>Strategic use of capital </li></ul><ul><li>Building collaborations </...
High-Risk, High-Reward Ventures New Business Models to Accelerate Research <ul><li>Funded $126 million in research to date...
Separating what we  need to do in science and what we need to do in the culture of science to accelerate curing diseases
Urgent Need to Refocus the Global Medical Research Enterprise <ul><li>Current research infrastructure has led to great adv...
Get involved with  FasterCures Visit us online and get the latest  FasterCures  information, publications, podcasts, video...
Partnering for Cures will bring together philanthropists, medical research foundations, and biopharmaceutical companies th...
Upcoming SlideShare
Loading in …5
×

FasterCures Presentation: Fostering innovation while delivering treatments and technologies to large markets

895 views

Published on

FasterCures' Margaret Anderson presents at the 2009 BioEconomy Summit Healthcare Policy Session 2: Affordability and Access. Presents new business models to accelerate research.

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

FasterCures Presentation: Fostering innovation while delivering treatments and technologies to large markets

  1. 1. Margaret Anderson COO June 25, 2009 BioEconomy Summit Healthcare Policy Session 2: Affordability and Access Fostering innovation while delivering affordable treatments and technologies to large markets
  2. 2. Components Essential to Successful Innovation in Disease Research <ul><li>Research roadmaps </li></ul><ul><li>New technology applications </li></ul><ul><li>Patient data utilization in research </li></ul><ul><li>Human capital </li></ul><ul><li>Clear federal guidance on technologies & approaches </li></ul><ul><li>Guidelines for public-private partnerships </li></ul><ul><li>Global perspective of the drug discovery and development process </li></ul><ul><li>Collaboration on patient registries and recruitment for clinical trials </li></ul><ul><li>Online tools to facilitate collaboration & interaction </li></ul><ul><li>Increased awareness of the importance of translational research programs </li></ul><ul><li>Effective communication of the complexity and value of medical research to the public </li></ul><ul><li>Advocacy behind key public policy issues (i.e., privacy, IP) </li></ul><ul><li>Organizational transformation to address emerging research needs </li></ul><ul><li>Risk-sharing on pre-competitive tools </li></ul><ul><li>More focus on translational research at NIH </li></ul><ul><li>Increased funding and predictable rewards structure for very novel, high-risk research </li></ul><ul><li>Standardization of clinical terms </li></ul><ul><li>Information portal for best practices </li></ul><ul><li>Goal-oriented intellectual property arrangements </li></ul>RESEARCH RESOURCES RESEARCH INFRASTRUCTURE RESEARCH ENVIRONMENT
  3. 3. Addressing Challenges within the Traditional Research System
  4. 4. Key Issues Affecting Progress <ul><li>Infrastructure </li></ul><ul><li>Institutional stakeholders’ resistance to changing infrastructure and rewards systems – in areas such as publication, tenure, grants, and intellectual property – to promote collaboration and innovation; </li></ul><ul><li>Lack of institutionalized communication and data exchange between basic and clinical researchers; </li></ul><ul><li>Inadequate opportunities for cross-disciplinary training and practice </li></ul>
  5. 5. Key Issues Affecting Progress <ul><li>Research Environment </li></ul><ul><li>Highly specialized, reductionist approach to scientific inquiry </li></ul><ul><li>Little funding or reward available for high-risk research </li></ul><ul><li>Limited collaboration on “big picture” problems </li></ul><ul><li>Conflict-of-interest challenges in public-private partnerships </li></ul><ul><li>Lack of public understanding of the disease research challenges </li></ul><ul><li>Insufficient focus on translating basic research into clinical application; </li></ul><ul><li>Inadequate dissemination of previous research efforts – especially failures; </li></ul><ul><li>Failure to aggregate funding across organizational lines to achieve larger scale impact </li></ul>
  6. 6. Valley of Death <ul><li>Basic research is the earliest stage of research, carried out for the advancement of knowledge, without necessarily any regard to its application to practical problems. </li></ul>Translational research is the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment and prevention of human disease – the critical bridge between basic research and clinical research. Clinical research is research in human subjects aiming toward approved treatments for patients.
  7. 7. Finding Big Ideas in Small Spaces: New Business Models to Accelerate Research
  8. 8. Philanthropic Research Funding: Small in Size, Unique in its Role Foundations and other private funds ($2.5B) Estimated health research expenditure in the US by source, 2006 USD billions, percent (100%=$116.1B) Pharmaceuticals ($37.0B) Medical device industry ($9.5B) Biotech ($18.2B) NIH ($28.5B) Universities ($8.3B) State and local funds ($2.9B) Other federal funds ($9.2B) Source: “ 2006 Investment in U.S. Health Research ”, Research!America; Moses, H. et al, “ Financial Anatomy of Biomedical Research ,” Journal of American Medical Association, vol.294, No.11, September 21, 2005 <ul><li>Philanthropic money accounts for only 2% of total funding; however, it fills a unique niche by: </li></ul><ul><li>Filling gaps in funding research that is high risk but also with potential of high return </li></ul><ul><li>Being virtually the only source of funding for innovative research in the current environment of flat NIH funding </li></ul>
  9. 9. Finding Big Ideas in Small Spaces The Redstone Acceleration and Innovation Network Passion Capital De-Risking Investments Patient Access Clinical Trial and Research Networks Intellectual Capacity Research Discipline Science Management Advocacy T he R edstone A cceleration and I nnovation N etwork
  10. 10. Venture Philanthropies’ Innovative Practices <ul><li>Strategic use of capital </li></ul><ul><li>Building collaborations </li></ul><ul><li>Streamlining the grantmaking process </li></ul><ul><li>Sharing information </li></ul>
  11. 11. High-Risk, High-Reward Ventures New Business Models to Accelerate Research <ul><li>Funded $126 million in research to date, 2/3 for translational research </li></ul><ul><li>Funded testing of over 100 therapeutic targets for Parkinson’s Disease </li></ul><ul><li>Partnership with Elan Corp. gives them first look at promising projects </li></ul><ul><li>Funded more than $66 million since 2005 </li></ul><ul><li>Actively supports more than 30 new treatments in development – 4 FDA-approved </li></ul><ul><li>Partners include Vertex Pharmaceuticals, Parion Sciences, PTC Therapeutics, Inspire Pharmaceuticals, Gilead Sciences, Altus Pharmaceuticals </li></ul><ul><li>Raised $102 million to fund 70 labs worldwide </li></ul><ul><li>4 new treatments approved in 4 years </li></ul><ul><li>10 clinical trials facilitated by Multiple Myeloma Research Consortium </li></ul><ul><li>30 MMRF-funded compounds now in preclinical studies and clinical trials </li></ul>
  12. 12. Separating what we need to do in science and what we need to do in the culture of science to accelerate curing diseases
  13. 13. Urgent Need to Refocus the Global Medical Research Enterprise <ul><li>Current research infrastructure has led to great advances in knowledge of human health and disease; but it is not a good system for developing therapies for patients </li></ul>studying biology curing diseases
  14. 14. Get involved with FasterCures Visit us online and get the latest FasterCures information, publications, podcasts, video clips, and other multimedia resources Stay informed, get relevant, up-to-date news stories in biomedical research delivered to you twice-weekly Track our progress through our quarterly newsletter featuring program developments and offerings Talk to us. Respond and comment on our blogs about the latest issues, trends, and findings that impact medical research and discovery Find and follow us
  15. 15. Partnering for Cures will bring together philanthropists, medical research foundations, and biopharmaceutical companies that can accelerate the development and approval of new therapies patients need.

×